Tags

Type your tag names separated by a space and hit enter

Cardiac-specific activation of Cre expression at late fetal development.
Biochem Biophys Res Commun. 2007 Jul 27; 359(2):209-13.BB

Abstract

In a first step towards dissecting molecular mechanisms that contribute to the development of cardiac diseases, we have generated transgenic mice that express a Cre-GFP fusion protein under the transcriptional control of a 4.3kb murine cardiac Troponin I gene (cTnI) promoter. Cre-GFP expression, similar in three transgenic lines, is described in one line. In mouse embryos, transgenic for the Cre-GFP and ROSA lacZ reporter allele, first Cre-mediated recombination appeared at 16.5 dpc selectively at the heart. Like the endogenous cTnI gene, transgenic Cre expression showed a slow rise through fetal development that increased neonatally. Bitransgenic hearts, stained at 30 days of age, showed intense signals in ventricular and atrial myocytes while no recombination occurred in other tissues. The delayed onset of Cre activity in cTnI-Cre mice could provide a useful genetic tool to evaluate the function of loxP targeted cardiac genes without interference of recombination during early heart development.

Authors+Show Affiliations

Max-Planck-Institut für Medizinische Forschung, Abteilung Zellphysiologie, Heidelberg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17540338

Citation

Opherk, Jan P., et al. "Cardiac-specific Activation of Cre Expression at Late Fetal Development." Biochemical and Biophysical Research Communications, vol. 359, no. 2, 2007, pp. 209-13.
Opherk JP, Yampolsky P, Hardt SE, et al. Cardiac-specific activation of Cre expression at late fetal development. Biochem Biophys Res Commun. 2007;359(2):209-13.
Opherk, J. P., Yampolsky, P., Hardt, S. E., Schoels, W., Katus, H. A., Koenen, M., & Zehelein, J. (2007). Cardiac-specific activation of Cre expression at late fetal development. Biochemical and Biophysical Research Communications, 359(2), 209-13.
Opherk JP, et al. Cardiac-specific Activation of Cre Expression at Late Fetal Development. Biochem Biophys Res Commun. 2007 Jul 27;359(2):209-13. PubMed PMID: 17540338.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardiac-specific activation of Cre expression at late fetal development. AU - Opherk,Jan P, AU - Yampolsky,Peter, AU - Hardt,Stefan E, AU - Schoels,Wolfgang, AU - Katus,Hugo A, AU - Koenen,Michael, AU - Zehelein,Jörg, Y1 - 2007/05/21/ PY - 2007/04/26/received PY - 2007/05/06/accepted PY - 2007/6/2/pubmed PY - 2007/8/7/medline PY - 2007/6/2/entrez SP - 209 EP - 13 JF - Biochemical and biophysical research communications JO - Biochem Biophys Res Commun VL - 359 IS - 2 N2 - In a first step towards dissecting molecular mechanisms that contribute to the development of cardiac diseases, we have generated transgenic mice that express a Cre-GFP fusion protein under the transcriptional control of a 4.3kb murine cardiac Troponin I gene (cTnI) promoter. Cre-GFP expression, similar in three transgenic lines, is described in one line. In mouse embryos, transgenic for the Cre-GFP and ROSA lacZ reporter allele, first Cre-mediated recombination appeared at 16.5 dpc selectively at the heart. Like the endogenous cTnI gene, transgenic Cre expression showed a slow rise through fetal development that increased neonatally. Bitransgenic hearts, stained at 30 days of age, showed intense signals in ventricular and atrial myocytes while no recombination occurred in other tissues. The delayed onset of Cre activity in cTnI-Cre mice could provide a useful genetic tool to evaluate the function of loxP targeted cardiac genes without interference of recombination during early heart development. SN - 0006-291X UR - https://www.unboundmedicine.com/medline/citation/17540338/Cardiac_specific_activation_of_Cre_expression_at_late_fetal_development_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(07)00987-4 DB - PRIME DP - Unbound Medicine ER -